Replacing Opioids with Digital Tech for Pain at CES 2017

Replacing Opioids with Digital Tech for Pain at CES 2017
This post was published on the now-closed HuffPost Contributor platform. Contributors control their own work and posted freely to our site. If you need to flag this entry as abusive, send us an email.

Pain management is a growing story at CES 2017. I covered the topic of Sleep and Pain at CES one year ago in the Huffington Post, and this year, the category has grown in both number of innovations and mode of pain management. At CES 2017, there were exhibitors of FDA-approved devices, sleep-and-pain focused tech, wristbands for relaxation and nausea-management, and a $5,999 device for calming meditation that’s being used in addiction programs.

What’s driving growth and acceptance of this health tech segment is the opioid crisis which has become a public health epidemic across the U.S. The raw statistic is that dozens of people die everyday due to drug overdose. Underneath that number is the fact that the mortality rate for white men in America stopped declining due to what Anne Case of Princeton University has called, “deaths of despair.” A contributor to the flatlining of mortality declines for white males is the dramatically growing use of opioids and other drugs in the post-Recession era.

“Chronic pain not caused by cancer is among the most prevalent and debilitating medical conditions but also among the most controversial and complex to manage,” according to Dr. Nora Volkow and Dr. Thomas Mclellan who co-authored a review article on the topic of opioid abuse in chronic pain in the New England Journal of Medicine (March 31, 2016). Over 30% of Americans have some sort of acute or chronic pain, and the prevalence among older adults is over 40%. Opioid analgesics are now the most commonly prescribed class of medications in the U.S., the authors attest.

At CES 2017, the Digital Health Summit track of programming included a session on digital tech for pain called Dying to Get High – Tackling the Opioid Epidemic. The panel included clinician innovators developing digital approaches to managing pain, including Virtual Reality (VR) headsets, digital therapeutics (medications plus mobile health apps), and medications delivered through smart implants. “Codeine, fentanyl, oxycodone, heroin: these are all opioid substances that are fueling the crisis that we have,” Dr Arshya Vahabzadeh, Director of Digital Health at the Harvard Medical School, listed as he introduced the panel.

At CES 2017, several exhibitors featured non-invasive personal health devices that aim to address the pain management challenge without drugs. At the most regulated and science-based end of the spectrum of pain-tech options at CES was Quell, developed and marketed by NeuroMetrix. This company’s provenance has been in the FDA regulated medical device space focused on neurology, spinning off from the Harvard-MIT Division of Health Sciences and Technology in 1996. Thus, the company has a long history dealing with pain through neurostimulation in acute care settings. When I met with the company one year ago, they had recently launched Quell following FDA approval, an OTC (over-the-counter) consumer-facing medical device that is based on the company’s understanding of pain triggers. The Quell wraps around the calf, regardless of the site of pain (back, hip, knee, wherever). Quell stimulates sensory nerves which then triggers the body’s natural pain relief response. NeuroMetrix’s clinical studies claim that 81% of users reported an improvement in chronic pain.

Quell was one of several innovations focused on pain at CES 2017. Related devices targeted sleep, with a dozen exhibitors in the CES Sleep Tech Marketplace. Among the sleep tech’s were the Sleep Number 360 AI-smart bed, which won a CES 2017 innovation award; and, the Beddit sleep tracker under-the-sheet bed sensor “with nothing to wear” that integrates with the eClinicalWorks electronic health records system.

Another related category was nausea, where the most prominent player in this segment was the ReliefBand, a wristband using neuromodulation to regulate nausea, “retching,” and vomiting, according to its promotions. This FDA-cleared device is being marketed to address nausea due to auto/driving, virtual reality, pregnancy, boating, cruising, trains, flights, gaming, amusements (like Ferris wheel rides), and vertigo. Forbes magazine’s lifestyle section called the ReliefBand one of the “best new travel accessories for the road warrior.”

These devices are part of a growing supply side responding to the consumer/patient demand to treat pain without drugs. Dr. Vahabzadeh called the opioid crisis a “doctor and healthcare system-driven crisis.” As evidence-based digital options come to market to deal with this challenge, consumers can take back some power from the healthcare system to reverse this crisis.

Popular in the Community


What's Hot